CD8A and melanoma: The combined treatment with these IMT-loaded nanocarriers and anti-CTLA-4 induced a selective Treg depletion in melanoma-bearing mice, which reverted the immunosuppressive environment leading to a higher CD8+ T cells accumulation and activation in the tumoral tissue.